Pharmaceutical News

RSS

Fitch Ratings revises Merck & Co.'s outlook

Fitch Ratings has affirmed Merck & Co.'s (Merck) ratings, and revised the Rating Outlook to Negative from Stable.

18 Nov 2008

Celprogen introduces in vivo model for human glioblastoma

Celprogen Inc. has announced that they have successfully validated an in vivo model system for testing efficacy of cancer drugs and also novel drug candidates for Human Glioblastoma.

18 Nov 2008

Altus Pharmaceuticals reaffirms plan to submit NDA for Trizytek

Altus Pharmaceuticals Inc. announced today that it is reaffirming its plan to submit a new drug application (NDA) for Trizytek TM (liprotamase) in the first-half of 2009.

18 Nov 2008

Simple, inexpensive method for detecting contaminants in heparin

The blood-thinning drug heparin is highly effective when used to prevent and treat blood clots in veins, arteries and lungs, but earlier this year its reputation as a lifesaver was sullied when contaminated heparin products caused serious allergic reactions that led to a large number of deaths.

17 Nov 2008

Governments urged to take broader perspective when considering whether to fund vaccines

Including quality-of-life impacts in assessments of national vaccination programs would lead to many benefits, including improved productivity and less sick leave for parents, according to an editorial co-authored by a University of New South Wales (UNSW) researcher, that has appeared in the Lancet Infectious Diseases.

17 Nov 2008

Osteoporosis drugs may prevent future bone growth

Patients who start and eventually stop regimens of a common class of osteoporosis drugs called bisphosphonates may be unable to benefit from parathyroid hormone (PTH), which can rebuild bone mass lost due to advanced stage osteoporosis. PTH has been proven to increase the volume and strength of the honeycomb-like bone infrastructure, the inner mesh that begins to diminish in old age.

13 Nov 2008

TheraQuest's IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA

TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.

13 Nov 2008

Swiss approval for Zevtera in treatment of complicated skin and soft tissue infections

Swissmedic, the Swiss agency for therapeutic products, has approved Zevtera (ceftobiprole medocaril) for the treatment of complicated skin and soft tissue infections, including diabetic foot infections which have not spread to the bone.

13 Nov 2008

GlaxoSmithKline to acquire Genelabs Technologies

GlaxoSmithKline has announced that Gemstone Acquisition Corporation, a wholly-owned subsidiary of GSK, is commencing a cash tender offer to purchase all outstanding shares of common stock of Genelabs Technologies, Inc., for $1.30 in cash without interest and less any required withholding taxes.

12 Nov 2008

FDA warns public of extortion scam by FDA impersonators

The U.S. Food and Drug Administration is warning consumers about a fraudulent scheme to extort money from consumers by callers who falsely identify themselves as "FDA special agents" or other FDA officials.

12 Nov 2008

Calls for a more flexible approach to vaccine funding

Governments should take a broader perspective - including quality-of-life impacts - when considering whether to fund vaccines, according to a paper from the University of New South Wales (UNSW).

11 Nov 2008

Xamiol gel provides relief for scalp psoriasis

A new, once-daily treatment gel is available on prescription today for the itching, flaking and soreness caused by the common condition scalp psoriasis.

10 Nov 2008

FDA seizes Heparin from Cincinnati manufacturer

As part of the U.S. Food and Drug Administration's ongoing efforts to ensure that heparin for patients remains safe, the government today seized 11 lots of heparin from Celsus Laboratories Inc. in Cincinnati, Ohio.

7 Nov 2008

FDA approves Ranexa for the treatment of chronic angina

CV Therapeutics, Inc. has announced that the U.S. Food and Drug Administration (FDA) has approved a new, first line indication for Ranexa(R) (ranolazine extended-release tablets) for the treatment of chronic angina.

7 Nov 2008

Fenfluramine shown to have serious long-term effects

Fenfluramine, the appetite suppressant drug banned in the US in 1997 due to fears over its links to heart conditions, has been shown to have serious long-term effects.

6 Nov 2008

SALVAT submits complete response to FDA approvable letter for CETRAXAL

SALVAT announced today the submission of the response to the FDA Approvable Letter for CETRAXAL (Ciprofloxacin 0.2% Otic Solution in Single Dose Containers).

6 Nov 2008

NCPA statement on Florida study about prescription drug prices

Health Service Online has published a study called "Variation in Drug Prices at Pharmacies: Are Drug Prices Higher in Poor Areas," by Walid F. Gellad.

6 Nov 2008

Investigational drug, MK-677 shows promise for reducing age-related frailty

Researchers at the University of Virginia Health System report that a daily single oral dose of an investigational drug, MK-677, increased muscle mass in the arms and legs of healthy older adults without serious side effects, suggesting that it may prove safe and effective in reducing age-related frailty.

5 Nov 2008

Medicaid policies vary widely for biologic disease-modifying antirheumatic drugs

Patients with inflammatory diseases such as rheumatoid arthritis now have many more treatment options than in the past, including biologic disease-modifying antirheumatic drugs (DMARDs).

5 Nov 2008